Opioid antagonists as potential therapeutics for ischemic stroke

N. Peyravian, Emre Dikici, Sapna K Deo, Michal J Toborek, Sylvia Daunert

Research output: Contribution to journalShort survey

Abstract

Chronic use of prescription opioids exacerbates risk and severity of ischemic stroke. Annually, 6 million people die from stroke worldwide and there are no neuroprotective or neurorestorative agents to improve stroke outcomes and promote recovery. Prescribed opioids such as morphine have been shown to alter tight junction protein expression, resulting in the disruption of the blood brain barrier (BBB), ultimately leading to stroke pathogenesis. Consequently, protection of the BBB has been proposed as a therapeutic strategy for ischemic stroke. This perspective addresses the deficiency in stroke pharmacological options and examines a novel application and repurposing of FDA-approved opioid antagonists as a prospective neuroprotective therapeutic strategy to minimize BBB damage, reduce stroke severity, and promote neural recovery. Future directions discuss potential drug design and delivery methods to enhance these novel therapeutic targets.

Original languageEnglish (US)
Article number101679
JournalProgress in Neurobiology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Narcotic Antagonists
Stroke
Blood-Brain Barrier
Opioid Analgesics
Therapeutics
Tight Junction Proteins
Drug Design
Morphine
Prescriptions
Pharmacology

Keywords

  • Blood brain barrier
  • Ischemic stroke
  • Naloxone
  • Naltrexone
  • Neuroprotection
  • Opioid antagonist

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Opioid antagonists as potential therapeutics for ischemic stroke. / Peyravian, N.; Dikici, Emre; Deo, Sapna K; Toborek, Michal J; Daunert, Sylvia.

In: Progress in Neurobiology, 01.01.2019.

Research output: Contribution to journalShort survey

@article{d8c15f2342e14a0d9ad0625972e9c177,
title = "Opioid antagonists as potential therapeutics for ischemic stroke",
abstract = "Chronic use of prescription opioids exacerbates risk and severity of ischemic stroke. Annually, 6 million people die from stroke worldwide and there are no neuroprotective or neurorestorative agents to improve stroke outcomes and promote recovery. Prescribed opioids such as morphine have been shown to alter tight junction protein expression, resulting in the disruption of the blood brain barrier (BBB), ultimately leading to stroke pathogenesis. Consequently, protection of the BBB has been proposed as a therapeutic strategy for ischemic stroke. This perspective addresses the deficiency in stroke pharmacological options and examines a novel application and repurposing of FDA-approved opioid antagonists as a prospective neuroprotective therapeutic strategy to minimize BBB damage, reduce stroke severity, and promote neural recovery. Future directions discuss potential drug design and delivery methods to enhance these novel therapeutic targets.",
keywords = "Blood brain barrier, Ischemic stroke, Naloxone, Naltrexone, Neuroprotection, Opioid antagonist",
author = "N. Peyravian and Emre Dikici and Deo, {Sapna K} and Toborek, {Michal J} and Sylvia Daunert",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.pneurobio.2019.101679",
language = "English (US)",
journal = "Progress in Neurobiology",
issn = "0301-0082",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Opioid antagonists as potential therapeutics for ischemic stroke

AU - Peyravian, N.

AU - Dikici, Emre

AU - Deo, Sapna K

AU - Toborek, Michal J

AU - Daunert, Sylvia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Chronic use of prescription opioids exacerbates risk and severity of ischemic stroke. Annually, 6 million people die from stroke worldwide and there are no neuroprotective or neurorestorative agents to improve stroke outcomes and promote recovery. Prescribed opioids such as morphine have been shown to alter tight junction protein expression, resulting in the disruption of the blood brain barrier (BBB), ultimately leading to stroke pathogenesis. Consequently, protection of the BBB has been proposed as a therapeutic strategy for ischemic stroke. This perspective addresses the deficiency in stroke pharmacological options and examines a novel application and repurposing of FDA-approved opioid antagonists as a prospective neuroprotective therapeutic strategy to minimize BBB damage, reduce stroke severity, and promote neural recovery. Future directions discuss potential drug design and delivery methods to enhance these novel therapeutic targets.

AB - Chronic use of prescription opioids exacerbates risk and severity of ischemic stroke. Annually, 6 million people die from stroke worldwide and there are no neuroprotective or neurorestorative agents to improve stroke outcomes and promote recovery. Prescribed opioids such as morphine have been shown to alter tight junction protein expression, resulting in the disruption of the blood brain barrier (BBB), ultimately leading to stroke pathogenesis. Consequently, protection of the BBB has been proposed as a therapeutic strategy for ischemic stroke. This perspective addresses the deficiency in stroke pharmacological options and examines a novel application and repurposing of FDA-approved opioid antagonists as a prospective neuroprotective therapeutic strategy to minimize BBB damage, reduce stroke severity, and promote neural recovery. Future directions discuss potential drug design and delivery methods to enhance these novel therapeutic targets.

KW - Blood brain barrier

KW - Ischemic stroke

KW - Naloxone

KW - Naltrexone

KW - Neuroprotection

KW - Opioid antagonist

UR - http://www.scopus.com/inward/record.url?scp=85070859279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070859279&partnerID=8YFLogxK

U2 - 10.1016/j.pneurobio.2019.101679

DO - 10.1016/j.pneurobio.2019.101679

M3 - Short survey

JO - Progress in Neurobiology

JF - Progress in Neurobiology

SN - 0301-0082

M1 - 101679

ER -